WALTHAM, Mass., July 30, 2025 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, antibody-based ...
Immunitas Therapeutics Inc. has revealed preclinical data supporting development of its potentially first-in-class, fully human anti-CD161 antibody, IMT-380. CD161-expressing T-cell subsets have been ...
The MarketWatch News Department was not involved in the creation of this content. IMT-380 induces selective depletion of pathogenic CD161+ T cells, reducing inflammatory cytokine expression across in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results